WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Inc Stock

$1.11+0.01 (+0.91%)
Updated Jul 22, 2024
PLX Price
$1.11
Fair Value Price
N/A
Market Cap
$81.38M
52 Week Low
$1.02
52 Week High
$2.09
P/E
11.1x
P/B
2.73x
P/S
1.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$59.65M
Earnings
$6.85M
Gross Margin
62.3%
Operating Margin
14.1%
Profit Margin
11.5%
Debt to Equity
2.02
Operating Cash Flow
$6M
Beta
0.63
Next Earnings
Aug 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PLX Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PLX is good value based on its earnings relative to its share price (11.1x), compared to the US market average (29.85x)
P/E vs Market Valuation
PLX is good value based on its earnings relative to its share price (11.1x), compared to the US Biotechnology industry average (-27.86x)
P/E vs Industry Valuation
PLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PLX due diligence checks available for Premium users.

Be the first to know about important PLX news, forecast changes, insider trades & much more!

Valuation

PLX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
11.1x
Industry
-27.86x
Market
29.85x
PLX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PLX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

PLX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.73x
Industry
6.3x
PLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PLX's financial health

Profit margin

Revenue
$3.7M
Net Income
-$4.6M
Profit Margin
-122.6%
PLX's Earnings (EBIT) of $8.41M... subscribe to Premium to read more.
Interest Coverage Financials
PLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$89.8M
Liabilities
$60.0M
Debt to equity
2.02
PLX's short-term assets ($75.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLX's short-term assets ($75.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.2M
Investing
-$606.0k
Financing
$0.0
PLX's operating cash flow ($5.87M)... subscribe to Premium to read more.
Debt Coverage Financials

PLX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PLX$81.38M+0.91%11.10x2.73x
CMRX$81.47M+1.00%-0.97x0.47x
PMVP$81.28M+1.28%-1.19x0.38x
BYSI$81.18M-5.45%-3.85x-3.03x
GNTA$81.07M-1.33%-6.39x3.65x

Protalix Biotherapeutics Stock FAQ

What is Protalix Biotherapeutics's quote symbol?

(NYSEMKT: PLX) Protalix Biotherapeutics trades on the NYSEMKT under the ticker symbol PLX. Protalix Biotherapeutics stock quotes can also be displayed as NYSEMKT: PLX.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.

What is the 52 week high and low for Protalix Biotherapeutics (NYSEMKT: PLX)?

(NYSEMKT: PLX) Protalix Biotherapeutics's 52-week high was $2.09, and its 52-week low was $1.02. It is currently -46.89% from its 52-week high and 8.82% from its 52-week low.

How much is Protalix Biotherapeutics stock worth today?

(NYSEMKT: PLX) Protalix Biotherapeutics currently has 73,316,084 outstanding shares. With Protalix Biotherapeutics stock trading at $1.11 per share, the total value of Protalix Biotherapeutics stock (market capitalization) is $81.38M.

Protalix Biotherapeutics stock was originally listed at a price of $850.00 in May 15, 1998. If you had invested in Protalix Biotherapeutics stock at $850.00, your return over the last 26 years would have been -99.87%, for an annualized return of -22.54% (not including any dividends or dividend reinvestments).

How much is Protalix Biotherapeutics's stock price per share?

(NYSEMKT: PLX) Protalix Biotherapeutics stock price per share is $1.11 today (as of Jul 22, 2024).

What is Protalix Biotherapeutics's Market Cap?

(NYSEMKT: PLX) Protalix Biotherapeutics's market cap is $81.38M, as of Jul 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Protalix Biotherapeutics's market cap is calculated by multiplying PLX's current stock price of $1.11 by PLX's total outstanding shares of 73,316,084.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.